Reinjection in Patients with Intraocular Inflammation Development after Intravitreal Brolucizumab Injection.

Purpose: To investigate the outcomes of brolucizumab reinjection after intraocular inflammation (IOI) development.

Methods: This retrospective study analyzed patients with brolucizumab injections from April 2021 to January 2024. Patients who developed IOI after brolucizumab were included and categorized into subgroups depending on reinjection, discontinuation, and further IOI development.

Results: A total of 472 eyes of 432 patients received brolucizumab injections. Thirty-eight cases developed IOI at least once, and 25 continued brolucizumab. Sixteen cases had no more IOI events, and nine experienced a second or more IOI events. Among the nine cases, three maintained brolucizumab injections despite IOI recurrence. The incidence of IOI was 8.1% based on the number of eyes (38 of 472 eyes) and 2.0% based on the number of brolucizumab injections (50 of 2468 injections). The incidence of occlusive retinal vasculitis was 0.2% (one of 472 eyes). The recurrence rate was 23.7% (nine of 38 eyes). The average number of injections between the first brolucizumab injection and the injection date on which IOI first developed was 2.15 times in the No-reinjection group, 3.44 times in the No-IOI recurrence group, and 2.0 times in the Second IOI episode group. Time to IOI occurrence in cases with first IOI episode was 18.60 ± 16.73 days, with 15 cases developing IOI within one week.

Conclusions: This study elucidates the real-world incidence of brolucizumab associated IOIs, with a description of information related to reinjections after the IOI episodes. A comprehensive understanding of brolucizumab reinjection is essential for its optimal utilization.